• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS spectrums >Clinical management of restless legs syndrome in end-stage renal disease patients
【24h】

Clinical management of restless legs syndrome in end-stage renal disease patients

机译：临床管理在末期肾病患者中躁动腿综合征

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Restless legs syndrome (RLS) is a common neurological movement disorder, characterized by restless and unpleasant sensations in the deep inside of legs. The symptoms of RLS are less noticeable during daytime, but more prevalent at night. Therefore, the disorder can induce low quality of life, insomnia, and impairment of daytime activity. RLS in end-stage renal disease (ESRD) patients is especially problematic due to premature discontinuation of dialysis and increased mortality. The prevalence of RLS among dialysis patients is much higher compared to the prevalence of the same disorder in patients with normal renal functions. Even though there are recommended treatment guidelines for the general population established by Medical Advisory Board of the RLS foundation, which include the use of dopamine agonists, levodopa, gabapentin, benzodiazepines, and opioids, limited information is available on the effects of these therapies in ESRD patients. Since the existing clinical data were extrapolated from small sample sizes in short-term clinical trials, further clinical studies are still needed to better assess the efficacy, safety, and tolerability of these medications in patients with ESRD.
机译：躁动的腿综合征（RLS）是一种常见的神经运动障碍，其特征在于腿部内部的焦躁和不愉快的感觉。白天的RLS的症状不太明显，但晚上更普遍。因此，该疾病可以诱导低生命，失眠和白天活动的损害。由于透析的过早停止和增加死亡率，终末期肾病（ESRD）患者的RLS尤其有问题。与正常肾功能患者相同疾病的患病率相比，透析患者中​​RLS的患病率远高得多。尽管存在由RLS基金会的医疗咨询委员会建立的一般人口的推荐准则，包括使用多巴胺激动剂，Levodopa，Gabapentin，苯并二氮卓和阿片类药物，有限的信息可用于这些疗法在ESRD中的影响耐心。由于现有的临床数据在短期临床试验中从小样本尺寸外推，因此仍然需要进一步的临床研究以更好地评估这些药物在ESRD患者中的功效，安全性和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号